◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Immunovant Inc (IMVT) EBITDA 2018–TTM

Name: Immunovant Inc (IMVT) ebitda history 2018-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-10

Immunovant Inc annual ebitda for fiscal TTM was -$539 million, a decrease of 6.7% from -$505 million in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

IMVT Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-12-31	2018-03-31
EBITDA	($539M)	($505M)	($413M)	($259M)	($198M)	($157M)	($108M)	($66M)	$0M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IMVT Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
EBITDA	($153M)	($151M)	($109M)	($126M)	($120M)	($106M)	($111M)	($109M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

IONS EBITDA — Ionis Pharmaceuticals Inc
SYRE EBITDA — Spyre Therapeutics Inc.
CRNX EBITDA — Crinetics Pharmaceuticals Inc
PCVX EBITDA — Vaxcyte Inc
IBRX EBITDA — Immunitybio Inc
TGTX EBITDA — TG Therapeutics Inc

More IMVT metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All IMVT financial statements → Interactive IMVT charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.